NXTS vs ARGX vs INSM Stock Comparison

Nexentis Technologies, Argenx Se and Insmed Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.67B
P/E
31.3x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
5 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$27.04B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

8 decided of 12

Argenx Se leads on 5 of the 12 questions below (Argenx Se 5, Insmed 2, Nexentis Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSARGXINSMLeader
Larger companyMarket capitalisation $328.90K $58.67B $27.04B ARGX
Cheaper on earningsLower P/E, profitable companies only 0.0x 31.3x -44.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 32.8x — –
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +61.5% +240.0% INSM
More profitableNet margin, trailing twelve months — 32.3% -39.9% ARGX
Better return on capitalReturn on invested capital — — -41.1% –
Less leveragedLower net debt / EBITDA 0.8x — 1.1x NXTS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +7.7% -36.6% ARGX
Better 5-year returnAnnualised price return, 5 years -82.4%/yr +25.4%/yr +30.6%/yr INSM
Less volatileAnnualised volatility, 1 year 235.4% 37.7% 62.2% ARGX
Higher overall scoreMean of the five percentile scores vs peers 18/100 92/100 66/100 ARGX

Percentile Scorecard

NXTSARGXINSM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSARGXINSM
Valuation 7 #612 of 660 82 #122 of 660 70 #201 of 660
Growth 6 #585 of 619 96 #27 of 619 85 #91 of 619
Profitability 22 #462 of 595 99 #9 of 595 69 #186 of 595
Financial Health 38 #423 of 683 – 37 #428 of 683
Shareholder Returns – – 67 #153 of 459
Overall 18 92 66
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSARGXINSMSPY
1 month +229.2%+17.3%+23.9% -2.0%
3 months +12.0%+12.8%-2.1% -2.8%
6 months -52.0%+20.1%+11.0% +2.0%
Year to date -81.8%+14.2%-30.4% +10.6%
1 year -90.3%+7.7%-36.6% +12.2%
3 years -99.6%+96.0%+393.7% +68.1%
3 years, per year -84.2%+25.2%+70.3% +18.9%
5 years -100.0%+210.1%+280.3% +61.4%
5 years, per year -82.4%+25.4%+30.6% +10.1%
10 years -100.0%—+738.5% +248.5%
10 years, per year -61.8%—+23.7% +13.3%

Risk

MeasureNXTSARGXINSMSPY
Volatility, 1Y 235.4%37.7%62.2% 13.6%
Downside volatility, 1Y 158.4%35.2%61.0% 13.9%
Beta vs S&P 500, 1Y 4.330.540.55 1.00
Return / volatility, 1Y -0.380.20-0.59 0.90
Max drawdown, 5Y -100.0%-38.2%-56.5% -25.4%
From 52-week high -90.5%-9.3%-42.7% -3.2%
52-week high $22.54$1,058.90$211.41 $779.14
52-week low $0.48$663.93$91.88 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSARGXINSM
P/E now vs peer median 0.0xmedian 17.0x 31.4xmedian 17.0x -43.8xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 10.2xmedian 8.4x 17.5xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x —median 14.6x -48.6xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x —median 19.0x -42.3xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x —median 2.0x 36.6xmedian 2.0x
PEG now vs peer median 0.00median 0.43 0.30median 0.43 -2.40median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSARGXINSM
Revenue -$8.94M $5.82B $1.52B
Gross profit – $5.24B $1.28B
Operating income -$10.88M $1.74B -$563.99M
Net income -$16.14M $1.88B -$605.67M
Free cash flow -$4.50M – -$627.58M
R&D $798.00K $1.80B $944.39M
EPS (diluted) $-98.21 $28.43 $-2.77
Cash & equivalents $7.62M – $396.60M
Total debt $422.00K – $555.09M
Shares (diluted) 163.23K 66.03M 218.79M
Enterprise value -$25.11M $58.67B $22.08B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSARGXINSM
P/E 0.0x 31.4x -43.8x
P/FCF -0.1x – -42.3x
P/Operating cash flow -0.1x – -44.6x
P/S 0.0x 10.2x 17.5x
P/B 0.2x – 36.6x
P/Tangible book -0.2x – 45.2x
EV/EBITDA 0.8x – -48.6x
EV/EBIT 0.7x 34.1x -46.1x
EV/Revenue 0.9x 10.2x 17.1x
EV/FCF 1.8x – -41.4x
EV/Operating cash flow 1.8x – -43.6x
PEG (3Y EPS CAGR) 0.00 0.30 -2.40

Growth

14 metrics
MetricNXTSARGXINSM
Revenue growth (1Y) -4,238% 61.5% 240.0%
Revenue CAGR (3Y) -182.9% 80.5% 75.6%
Gross profit growth (1Y) – 62.2% 274.9%
Gross profit CAGR (3Y) – 80.0% 79.8%
Operating income growth (1Y) -127.3% 120.6% 51.3%
Operating income CAGR (3Y) -23.5% 85.1% 6.2%
Net income growth (1Y) -70.1% 22.5% 48.8%
Net income CAGR (3Y) -42.2% 115.5% 5.8%
EPS growth (1Y) -666.2% 20.9% 50.5%
EPS CAGR (3Y) -52.0% 104.8% 18.2%
Operating cash flow growth (1Y) -62.8% – 32.6%
Operating cash flow CAGR (3Y) -0.4% – -5.4%
Free cash flow growth (1Y) -65.5% – 30.7%
Free cash flow CAGR (3Y) -0.7% – -6.2%

Profitability

14 metrics
MetricNXTSARGXINSM
Gross margin – 90.0% 84.4%
EBITDA margin – – -35.1%
Operating margin – 29.9% -37.1%
Pretax margin – 32.6% -39.4%
Net margin – 32.3% -39.9%
FCF margin – – -41.3%
Operating cash flow margin 49.6% – -39.2%
Return on equity -218.6% – -81.9%
Return on assets -92.0% – -28.1%
Return on invested capital – – -41.1%
Return on capital employed -73.7% – -36.0%
Asset turnover -0.5x – 0.7x
Cash conversion (OCF / net income) 0.3x – 1.0x
Stock comp / revenue -11.0% – 11.0%

Financial Health

11 metrics
MetricNXTSARGXINSM
Debt / assets 2.3% – 24.9%
Debt / equity 0.2x – 0.8x
Net debt / EBITDA 0.8x – 1.1x
Debt / FCF -0.1x – -0.9x
Liabilities / assets 89.8% – 67.4%
Equity / assets 10.2% – 32.6%
Interest coverage – 10,120x -5.5x
Current ratio 3.7x – 2.9x
Quick ratio 3.2x – 2.4x
Cash ratio 3.2x – 1.9x
Altman Z-score -6.11 – 7.36

Shareholder Returns

7 metrics
MetricNXTSARGXINSM
Dividend yield – – –
Net buyback yield -2,794% – -0.4%
Shareholder yield -2,794% – -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSARGXINSM
Forward P/E – 32.8xFY2026 –
EPS, next fiscal year – $29.27FY2026 $-1.68FY2026
EPS growth, next FY – +49.6%FY2026 –
EPS growth, the year after – +32.0% –
Revenue, next fiscal year – $6.16BFY2026 $1.99BFY2026
Revenue growth, next FY – +44.9%FY2026 +227.7%FY2026
Revenue growth, the year after – +24.0% +59.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSARGXINSM
Held by institutions – 46.1% 100.0%
Institutions holding – 506 671
Change in shares held, QoQ – -2.0% +3.4%
Institutions buying – 263 369
Institutions selling – 162 230
Buyers to sellers – 1.62 1.60

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSARGXINSM
NXTS 1.00 0.17 0.00
ARGX 0.17 1.00 0.27
INSM 0.00 0.27 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, ARGX and INSM?

Argenx Se (ARGX) is the largest by market capitalisation: Nexentis Technologies (NXTS) $328.90K, Argenx Se (ARGX) $58.67B, Insmed (INSM) $27.04B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Argenx Se (ARGX) +61.5%, Insmed (INSM) +240.0%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Argenx Se (ARGX) 32.3%, Insmed (INSM) -39.9%).

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Nexentis Technologies (NXTS) -90.3%, Argenx Se (ARGX) +7.7%, Insmed (INSM) -36.6%. Over five years, Insmed (INSM) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Argenx Se (ARGX) +25.4%/yr, Insmed (INSM) +30.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Argenx Se (ARGX) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Argenx Se (ARGX) 37.7%, Insmed (INSM) 62.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, ARGX and INSM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.